Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab.
Manuela AltieriRocco CapuanoMiriana ConteGiovanna DonnarummaElena GrimaldiNicola CoppolaMassimiliano GaldieroAlessandro d'AmbrosioGioacchino TedeschiAntonio GalloPublished in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2022)
pwMS on NTZ develop and maintain a long-term humoral response after a full COVID-19 vaccination cycle comparable to their healthy peers, and these findings are relevant for clinicians called to counsel about COVID-19 mRNA vaccine timing and booster doses in pwMS treated with NTZ.